Trial | Treatment arms | PSA response* | Tumor response | ||||
---|---|---|---|---|---|---|---|
 |  | N | Response rate % | Statistical comparison | N | Objective response rate % | Statistical comparison |
Berry, 2002 [69] | mitoxantrone prednisone | 56 | 48†| p = 0.007 | 8 | 25 (PR) | p = NR |
 | prednisone | 63 | 24†|  | 9 | 22 (PR) |  |
Kantoff, 1999 [70] | mitoxantrone hydrocortisone | 96 | 18.7 | p = 0.41 | 116 | 7 (PR) | p = 0.38 |
 | hydrocortisone | 91 | 14.3 |  | 118 | 4 (PR) |  |
Tannock, 1996 [71] | mitoxantrone prednisone | 57 | 33 | p = 0.11 | NR | ||
 | prednisone | 54 | 22 |  |  |  |  |
Weissbach, 1998 [88] | mitomycin C | NR | 60 | 22 | NR | ||
 | epirubicin |  |  |  | 61 | 11 |  |
 | EMP |  |  |  | 55 | 9 |  |
Anderström, 1995 [72] | epiribucin MPA | NR | NR | ||||
 | EMP |  |  |  |  |  |  |
Laurie, 1992 [73] | 5-FU doxorubicin mitomycin-C (combined) | NR | 70 | 14 | NR | ||
 | 5-FU doxorubicin mitomycin-C (sequential) |  |  |  | 72 | 18 |  |
Saxman, 1992 [74] | cyclophosphamide doxorubicin methotrexate | NR | 16 | 18.8 (PR) | NR | ||
 | cyclophosphamide |  |  |  | 16 | 6 (PR) |  |
Murphy, 1988 [75] | doxorubicin cyclophosphamide | NR | 54 | 1 (PR) | p = NS | ||
 | cisplatin 5-FU cyclophosphamide |  |  |  | 46 | 0 |  |
 | methotrexate |  |  |  | 52 | 0 |  |
Stephens, 1984 [76] | doxorubicin cyclophosphamide | NR | 19 | 32 | p = 0.05 | ||
 | hydroxyurea |  |  |  | 24 | 4 |  |